skip to Main Content

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma

Istari Oncology Announces Publication of Phase 1 Data Showing PVSRIPO Immunotherapy Leads to Objective Responses in Patients with Treatment-Refractory Melanoma Objective responses observed in patients’ refractory to programmed death receptor-1 (PD-1) inhibitors and BRAF-targeted therapy Responses in both injected and…

Read More

Published Research in Nature Communications: PVSRIPO Leads to Robust, Functional T Cells — Critical for Antitumor Immunity

Istari Oncology Announces Publication of Data Showing the Investigational Immunotherapy PVSRIPO Leads to Robust, Functional T Cells — Critical for Antitumor Immunity Intratumoral PVSRIPO stimulates a specific inflammatory response dominated by type-I/III interferon (IFN)—crucial for effective antitumor T cell priming…

Read More
Back To Top
×Close search
Search